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Abstract. In normal common marmosets administration 
of the D-1/D-2 agonist apomorphine or the selective D-2 
agonist quinpirole caused a dose-dependent i crease in 
motor activity and induced stereotyped b haviour. Both 
the selective D-2 antagonist raclopride and the selective 
D-I antagonist SCH 23390 inhibited normal locomotor 
activity and induced catalepsy. Quinpirole- and apomor- 
phine-induced motor activity were potently inhibited by 
pretreatment with raclopride. The effects of quinpirole, 
but not apomorphine, were weakly inhibited by SCH 
23390. The selective D-1 partial agonist SKF 38393 de- 
creased motor activity and did not induce grooming, oral 
movements or other behaviours. SKF 38393 inhibited 
motor activity induced by the administration of quin- 
pirole but did not alter apomorphine-induced motor 
behaviour. Locomotor activity in normal common mar- 
mosets appears to be mediated mainly via D-2 systems. 
In contrast to rodents, administration f SKF 38393 does 
not induce behavioural activation and there does not 
appear to be a facilitating effect of D-1 systems on D-2 
function in the normal common marmoset. However, the 
ability of both SKF 38393 and SCH 23390 to inhibit 
quinpirole locomotor activity suggests some interaction 
between D-1 and D-2 systems to occur in this species. 
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Brain dopamine receptors are divided into D-1 adenylate 
cyclase linked sites and D-2 sites (Kebabian and Calne 
1979); some of the latter are negatively inked to adenyl- 
ate cyclase (Stoof and Kebabian 1981). Studies in rodents 
have shown specific behaviours related to each receptor 
population, but also indicate a functional linkage be- 
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tween the D-1 and D-2 sites in the intact animal (for 
review see Clark and White 1987; Waddington and 
O'Boyle 1987). For example, the D-2 agonist quinpirole 
and the mixed D-l/D-2 agonist apomorphine, but not 
the D-1 agonist SKF 38393, are able to induce locomotor 
hyperactivity and stereotypies in rats and mice. The ad- 
ministration of SKF 38393, however, does cause an in- 
crease in non-stereotyped grooming, sniffing and vac- 
uous chewing (Molloy and Waddington 1984, 1987). 
Also, administration f SKF 38393 potentiates the abil- 
ity of D-2 agonists uch as Ru 24296 (Mashurano and 
Waddington 1986) or bromocriptine (Jackson et al. 
1988) to induce stereotypy. Stimulation of both D-1 and 
D-2 receptors appears necessary for the induction of 
some oral components of stereotypy such as licking and 
gnawing. 
D-1 receptor activation i  rodents may therefore play 
a facilitating or permissive role in D-2-mediated behav- 
iours. A similar elationship can be observed using selec- 
tive D-I and D-2 antagonist drugs. Thus, administration 
to rats of the D-1 antagonist SCH 23390 will induce 
catalepsy identical to that produced by selective D-2 
antagonist drugs (Hoffman and Beninger 1985). In addi- 
tion, both D-1 antagonists and D-2 antagonist drugs, like 
raclopride (Ogren et at. 1986), can inhibit stereotypy 
induced by D-2 agonists. 
In normal rodents, D-2 receptors also manipulate 
D-l-mediated behaviours, but in a complex manner. For 
example, the grooming produced by SKF 38393 can be 
inhibited by both D-1 and D-2 antagonists (Murray and 
Waddington 1989a). In contrast, vacuous chewing in- 
duced by SKF 38393 is potentiated by selective D-2 
antagonists such as sulpiride, presumably by reducing 
D-2 inhibitory tone (Murray and Waddington 1989b). 
All these data point clearly to a mutual interaction 
between D-1 and D-2 receptors which can influence mo- 
tor behaviours in rodents. The functional outcome of 
manipulating brain dopamine receptors appears to de- 
pend on the resulting balance between D-1 and D-2 
systems. Such results may be of importance in designing 
new drug therapies for both neurological nd psychotic 
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disease in man.  However ,  it is unknown whether a similar 
re lat ionship exists between D-1 and D-2 receptors in man 
or non-human pr imates,  or  whether  selective D-1 or D-2 
drugs produce  similar behavioura l  effects to those ob-  
served in rodents.  Consequent ly,  in this invest igat ion we 
have studied the effect o f  manipu lat ing  D-1 and D-2 
receptors on the motor  activity o f  a pr imate  species, 
namely the common marmoset ,  seeking to undertake the 
same series o f  exper iments on which the roles of  D- I  and 
D-2 sites in motor  behaviour  in rats were established. 
Materials and methods 
Animals. Common marmosets (Callithrix jacchus) of either sex, 
weighing 280-420 g and aged 2-10 years at the beginning of the 
study, were used. The animals were housed either in pairs or alone 
under standard conditions at a temperature of 27 ° (± 1 o C) and 50 % 
relative humidity using a 12 h light-dark cycle (light on from 6.00 
to 18.00 hours). The animals had free access tofood pellets (Mazuri 
primate diet) and tap water, and in addition received a daily ration 
of fresh fruit and Mazuri marmoset j lly. 
Measurement of locomotor activity. Locomotor activity was mea- 
sured simultaneously in four aluminium cages (50 x 60 x 70 cm) 
with stainless steel grid doors (50 x 70 cm) identical to the animals, 
home cage but equipped with eight horizontally orientated s ts of 
infrared photocells. Across the cage three beams were located at 
floor level and one along each of the two perches. Other beams were 
directed from front to back of the cage at floor level and above ach 
perch. The number of light beam interruptions due to the animal's 
movements were accumulated in 10-rain intervals and recorded for 
120 min using a Commodore CBM 4032 computer. The animals 
were allowed to acclimatise tothe test cage for a minimum of 30 rain 
prior to drug treatment. 
Behavioural observations. In parallel to the automated recording of 
locomotor activity, the animals were observed through a one-way 
mirror. Motor behaviour was rated qualitatively to determine the 
presenced orabsence of stereotypy, co-ordination ofmovement, the 
degree of stimulation or inhibition, incidence of head twitches, wet 
dog shakes or grooming, oral movements and other obvious motor 
signs in 5-min intervals for 75 min after drug administration. In 
addition, a video recording of one animal in each treatment group 
was taken to allow post-hoc assessment of alterations in motor 
behaviour. 
Drug solutions. The following compounds were employed: SKF 
38393 (2,3,4,5-tetrahydro-7,8-dihydroxy- 1-phenyl- 1H-3-benzaze- 
pine hydrochloride; Research Biochemicals Inc., USA), SCH 23390 
(2-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1 }t-3-benzazepine- 
7-ol hemimaleate; Schering Corp., USA), apomorphine hydro- 
chloride (Macfarlan Smith Ltd., UK), quinpirote (LY 171555; 
tran s - ( - ) - 4aR - 4,4a, 5,6, 7, 8,8a, 9 - octahydro - 5 - propyl - 1H (or- 2H)- 
pyrazolo(3,4-g)quinoline monohydrochloride; Eli Lilly, USA), 
raclopride (S-(-)-3,5-dichloro-N-[(1-ethyl-2-pyrrolidinyl)methyl]- 
2-hydroxy-6-methoxy-benzamide; Astra, Sweden) and dom- 
peridone (Janssen, Belgium). The solutions were prepared under 
sterile conditions. All compounds, except domperidone, were dis- 
solved in sterile physiological saline and administered in a final 
volume of 1 ml/kg body weight. Domperidone was suspended in a 
few drops of ethanol (70%) and diluted to volume (2 ml/kg body 
weight) with 10% sucrose/water solution and administered by oral 
gavage. 
Dru9 treatments. Marmosets were randomly divided into groups of 
four and were subsequently treated with vehicle and the three doses 
of one test compound over the following weeks, allowing a 1-week 
recovery period between experiments. I dividual animals were max- 
imally employed in two such treatment groups with at least a 4-week 
period between experiments. A latin square design was used for the 
allocation of treatments within the groups. 
Dose-response studies. Animals were pretreated with domperidone 
(2 mg/kg PO) 30 rain prior to the subcutaneous (SC) administration 
of apomorphine (0.18, 0.75, t.5 mg/kg or vehicle) or intraperitoneal 
(IP) administration of quinpirole (0.15, 0.3, 0.6 mg/kg or vehicle) 
to prevent nausea or vomiting. Locomotor activity was recorded 
over the following 2-h period. The effects of SKF 38393 (1.25, 2.5, 
5.0 mg/kg IP or vehicle), SCH 23390 (0.31, 1.25, 5.0 mg/kg IP or 
vehicle) or raclopride (1.25, 5.0, 20.0 mg/kg IP or vehicle) were 
examined in an identical manner, except hat pretreatment with 
domperidone was not employed. To assess whether effects of SKF 
38393 were affected by domperidone treatment, a group of four 
animals was treated with either vehicle or SKF 38393 (5 mg/kg IP) 
alone or pretreated with domperidone (2mg/kg PO) 30 min prior 
to administration f SKF 38393 (5 mg/kg IP). 
Interaction studies. Animals were pretreated with domperidone 
(2 mg/kg PO) 15 min prior to the administration of either SKF 
38393 (1.25, 2.5, 5.0 mg/kg or vehicle IP) or SCH 23390 (0.31, 1.25, 
5.0mg/kg IP). A further 15 min later apomorphine (1.5 and 
0.75 mg/kg SC combined with SKF 38393) or quinpirole (0.6 mg/kg 
IP) were administered. Raclopride (0.31, 1.25, 5.0mg/kg IP or 
vehicle) was administered 15 rain prior to the administration of
apomorphine (1.5 mg/kg SC) or quinpirole (0.6 mg/kg IP). 
Data analysis. The mean ± SEM were calculated for time courses 
and accumulated locomotor counts of the different treatment 
groups. Statistical differences were calculated for accumulated loco- 
motor counts by the non-parametric Page test for ordered alter- 
natives using exact distributions. 
Results 
Effects of  apomorphine and quinpirole on motor 
behaviour 
Admin is t ra t ion  o f  apomorph ine  (0.18-1.5 mg/kg SC) or  
quinpirote (0.15~0.6mg/kg IP) dose-dependent ly  in- 
creased locomotor  act ivity in normal  common mar-  
mosets (Figs. 1 and 2). The effect o f  apomorph ine  was 
maximal  within 10 min o f  admin ist rat ion and lasted for 
about  60 min. Increasing doses did not  alter the durat ion 
of  act ion but  increased the intensity o f  motor  activity. 
Quinpiro le produced a more  sustained motor  effect, par-  
t icularly at the higher doses employed.  The effect o f  both  
apomorph ine  and quinpiro le was to produce an increase 
in motor  behaviour  which took  the form of  fast but  
contro l led movements.  In the highest doses tested both 
apomorph ine  and quinpiro le produced some stereotyped 
movements  in the form of  repetit ive grasping or body 
waving. An imals  did not  exhibit dyskinesia or dystonia  
and increased grooming was not  observed. 
Effects of raclopride and SCH 23390 
on motor behaviour 
Admin is t ra t ion  of  rac lopr ide (1.25-20 mg/kg IP) to nor-  
mal  common marmosets  decreased locomotor  activity in 
a dose-dependent  manner  (Fig. 3A). An imals  became 
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Fig. 1A, B. The effect of apomorphine on motor activity in ormal 
common marmosets. A Mean cumulative movement counts accu- 
mulated in 10-min intervals over 2 h (±SEM, n=4) of common 
marmosets pretreated with omperidone (2 mg/kg PO) 30 min prior 
to the subcutaneous administration of vehicle Go--) or 0.18 
Go--), 0.75 G []-) or 1.5 G I - )  mg/kg apomorphine. Error bars 
for the lower doses of apomorphine are omitted for clarity but were 
in the same range as those shown for the vehicle and apomorphine 
1.5 mg/kg SC treatment. B Mean cumulative movement counts 
accumulated over 2 h (±SEM, n=4) for the data shown in A. 
Locomotor activity was increased (P<0.01, Page test, ordered 
alternative: vehicle < 0.18 < 0.75 < 1.5 mg/kg apomorphine) 
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Fig. 2A, B. The effect of quinpirole on motor activity in ormal 
common marmosets. A Mean cumulative movement counts accu- 
mulated in 10-min intervals over2 h (:t:SEM, n=4) of common 
marmosets pretreated with domperidone (2 mg/kg PO) 30 min prior 
to the intraperitoneal administration of vehicle (--o--) or 0.15 
(-o--), 0.3 ( [] ) or 0.6 Gn--) mg/kg quinpirole, Error bars for 
the lower doses of quinpirole are omitted for clarity but were in the 
same range as those shown forthe vehicle and quinpirole 0.6 mg/kg 
IP treatment. B Mean cumulative movement counts accumulated 
over 2 h (_k SEM, n=4) for the data shown in A. Locomotor activ- 
ity was increased (P<0.01, Page test, ordered alternative: 
vehicle < 0.15 < 0.3 < 0.6 mg/kg quinpirole) 
sedated, cataleptic and akinetic after the administration 
of raclopride. Similarly, SCH 23390 (0.31-5.0 mg/kg IP) 
also caused a dose-dependent decrease in locomotor ac- 
tivity (Fig. 3B). Again, the effects of SCH 23390 were 
qualitatively identical to those of raclopride. 
Effects of raclopride or SCH 23390 on motor behaviour 
induced by apomorphine or quinpirole 
Quinpirole-induced locomotor activity (0.6 mg/kg IP) as 
well as stereotyped movements were dose-dependently 
inhibited by pretreatment of animals with SCH 23390 
(1.25 5.0mg/kg IP) or raclopride (0.31-5.0mg/kg IP) 
(Fig. 4A). The effects of raclopride and SCH 23390 were 
qualitatively similar, but raclopride had a much more 
marked effect and induced complete akinesia. 
The increase in motor activity and stereotypies 
produced by apomorphine (1.5 mg/kg SC) was abolished 
by pretreatment with raclopride (0.31-5.0mg/kg IP) 
(Fig. 4B). Indeed, treatment with raclopride produced 
complete akinesia and catalepsy. In contrast, the effect 
of apomorphine was not inhibited or qualitatively affect- 
ed by the pretreatment with SCH 23390 (1.25-5.0 mg/kg 
IP). 
Effects of SKF 38393 on motor behaviour 
Administration of SKF 38393 (1.25-5.0mg/kg SC) 
caused a dose-related ecrease in locomotor activity in 
normal common marmosets (Fig. 5). The effect of SKF 
38393 was apparent within 10 min and lasted for up to 
120 rain. The effect of SKF 38393 took the form of an 
inhibition of locomotor activity and reduced vigilance, 
but not catalepsy or complete akinesia. Animals did not 
exhibit stereotyped movements, purposeless chewing, 
dyskinesias, dystonia or grooming behaviour. 
SKF 38393 (5 mg/kg IP) administered alone (mean 
counts in 2 h 929 4-509) or in combination with dom- 
peridone (mean counts in 2 h 920±415) reduced loco- 
motor activity to the same extent compared to vehicle- 
treated animals (mean counts in 2 h t942±623) 
(P < 0.05). Again, the animals did not exhibit purpose- 
less chewing, tongue protrusions or other oral move- 
ments. Retching, vomiting, sialorhea and other signs of 
gastrointestinal discomfort were not observed. 
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Fig. 3A, B. The effect of raclopride or SCH 23390 on motor activity 
in normal common marmosets. Mean cumulative movement counts 
accumulated over 2 h (±SEM, n=4) for A vehicle, 1.25, .0 and 
20 mg/kg raclopride IP and B vehicle, 0.31, 1.25 and 5.0 mg/kg 
SCH 23390 IP. Locomotor activity was decreased by raclopride and 
SCH 23390 (P < 0.05, Page test, ordered alternative: 
vehicle > 0.125 > .0 > 20 mg/kg raclopride; P<0.05, Page test 
ordered alternative: vehicle > 0.31 > 1.25 > 5.0 mg/kg SCH 23390 
Effect of apomo~Thine or quinpirole in combination with 
SKF 38393 on motor behaviour 
Administration of quinpirole (0.6 mg/kg IP) induced an 
increase in locomotor activity (Fig. 6A). Stereotypies 
occasionally occurred in the group treated with quin- 
pirole alone. Pretreatment with SKF 38393 (1.25-5.0 mg/ 
kg IP) dose-dependently inhibited the effect of quin- 
pirole. No stereotypies, dyskinesias, dy tonia, purpose- 
less chewing or grooming was observed. 
Administration of apomorphine (1.5 and 0.75 mg/kg 
SC) also induced an increase in locomotor activity 
(Fig. 6B), but again in animals treated with 1.5 mg/kg 
apomorphine alone stereotypies were seen occasionally. 
Prior administration of SKF 38393 (1.25-5.0 mg/kg IP) 
did not alter the locomotor esponse produced by either 
dose of apomorphine, but SKF 38393 seemed to suppress 
the occurrence of  stereotyped movements. Grooming 
was seen occasionally, but purposeless chewing or other 
abnormal movements were not observed. 
Discussion 
The evidence available from rodent experiments clearly 
points to a reciprocal interaction between D-1 and D-2 
systems in the initiation and control of  motor  function. 
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Fig. 4A, B. The effect ofpretreatment wi h raclopride or SCH 23390 
on locomotor activity induced by quinpirole or apomorphine in
normal common marmosets. Mean cumulative movement counts 
accumulated over 2 h (± SEM, n= 4) for animals pretreated with 
2 mg/kg domperidone PO 15 min prior to administration of vehicle 
or SCH 23390 (1.25, 2.5 and 5.0 mg/kg IP, hatched bars) or raclo- 
pride (0.3t, 1.25 and 5.0 mg/kg IP, grey bars) and challenged with 
0.6 mg/kg quinpirole IP (A) or 1.5 mg/kg apomorphine SC (B) 
15 min later. Locomotor stimulation induced by quinpirole was 
decreased by SCH 23390 (P<0.05 Page test, ordered alterna- 
tive: vehicle> 1.25>2.5> 5.0 mg/kg SCH 23390) and ractopride 
(P<0.01 Page test, ordered alternative: vehicle>0.31>0.125> 
5.0 mg/kg raclopride). Locomotor stimulation induced by apomor- 
phine was decreased by raclopride (P<0.01, Page test, ordered 
alternative: vehicle > 1.25 > 2.5 > 5.0 mg/kg raclopride) 
In particular, in normal animals D-1 systems act to 
facilitate D-2 initiated motor behaviours. In the present 
study we have investigated using the same selective D-1 
and D-2 drug combinations whether a similar interaction 
occurs in a non-human primate species, namely the com- 
mon marmoset. 
Administration of the mixed D- l /D-2 agonist apo- 
morphine or the selective D-2 agonist quinpirole caused 
an increase in controlled motor activity, increased check- 
ing movement of the head and in high doses stereotyped 
movements of the limbs or the whole body. These effects 
are identical to those previously reported in normal com- 
mon marmosets treated with apomorphine (Ridley et al. 
1980) and other dopamine agonist drugs (Nomoto et al. 
1987). The behavioural changes also correspond to the 
effect of D-2 and D- l /D-2 agonists reported in rats, 
namely, increased locomotor activity and stereotypy. 
The administration of the D-2 antagonist raclopride 
or the D-1 antagonist SCH 23390 produced a similar 
effect on motor behaviour in normal monkeys. Both 
drugs caused a potent inhibition of all components of 
locomotor activity and in high doses catalepsy. This 
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Fig. 5A, B. The effect of SKF 38393 on locomotor activity in ormal 
common marmosets. A Mean cumulative mo ement counts accu- 
mulated in 10-rain intervals over 2 h (±SEM, n=4) of common 
marmosets following the intraperitoneal administration of vehicle 
@o--) or 1.25 ( • ), 2.5 (~D--) or 5.0 (--I--) mg/kg SKF 38393. 
Error bars for the lower doses of SKF 38393 are omitted for clarity 
but were in the same range as those shown forthe vehicle and SKF 
38393 5.0 mg/kg SC treatment. B Mean cumulative movement 
counts accumulated over 2 h (__+ SEM, n=4) for the data shown in 
A. Locomotor activity was decreased (P<0.01, Page test, ordered 
alternative: vehicle > 1.25 > 2.5 > 5.0 mg/kg SKF 38393) 
parallels the ability of both D-1 and D-2 antagonists to 
inhibit spontaneous locomotor activity and to induce 
catalepsy in rodents (Christensen et al. 1984). The data 
support a role for both D-1 and D-2 receptors in mediat- 
ing basal motor activity in common marmosets. 
Both SCH 23390 and raclopride inhibited the motor 
activity produced by quinpirole but the effect of raclo- 
pride was potent and that of SCH 23390 partial and 
weak. This would suggest a predominant effect of the D-2 
system in producing locomotor activity. Indeed, the ac- 
tions of apomorphine were potently and totally blocked 
by raclopride but there was no effect of SCH 23390. It 
therefore appears that D-1 systems play only a minor role 
in the initiation and control of locomotion induced by 
these dopamine agonists in normal common marmosets. 
In contrast o apomorphine and quinpirole, the ad- 
ministration of the selective D-1 partial agonist SKF 
38393 did not stimulate motor  behaviour. Rather, the 
drug caused a partial inhibition of normal motor func- 
tion without any qualitative changes in its components 
or the induction of catalepsy. These findings clearly con- 
trast with the effects of SKF 38393 in rats, where in- 
creased grooming but no inhibition of locomotor activity 
is observed (Dall'Olio et al. t988). It is unlikely that 
gastrointestinal side effects, which have been reported 
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Fig. 6A, B. The effect of apomorphine or quinpirole in combination 
with SKF 38393 on motor behaviour innormal comon marmosets. 
A Mean cumulative movement counts accumulated over 2 h 
(~SEM, n=4) of common marmosets pretreated with dom- 
peridone (2 mg/kg PO) 30 rain prior to administration ofquinpirole 
(0.6 mg/kg IP) alone or in combination with 1.25, 2.5 or 5.0 mg/kg 
IP SKF 38393 administered 15 rain previously. Locomotor activity 
was decreased (P<0.05, Page test, ordered alternative: 
quinpirole> 1.25 > 2.5> 5.0 mg/kg SKF 38393). B Mean cumula- 
tive movement counts accumulated over 2 h (± SEM, n=4) of 
common marmosets pretreated with domperidone (2mg/kg PO) 
30 min prior to administration of apomorphine (1.5 mg/kg SC, 
hatched bars or 0.75 mg/kg SC, open bars) alone or in combination 
with 1.25, 2.5 or 5.0 mg/kg IP SKF 38393 administered 15 min 
previously. Locomotor activity was not altered by SKF 38393 
administration 
after higher doses (10 or 30 mg/kg SC) of SKF 38393 in 
squirrel monkeys (Rupniak et al. 1991), are responsible 
for the reduction of locomotor activity seen in our experi- 
ments. This assumption is based on the observation that 
the degree of inhibition of locomotor activity as well as 
the behaviour were not altered by the peripheral D-2 
antagonist domperidone, It thus appears that using SKF 
38393 to act on D-1 receptors in normal primates results 
in effects which differ from those in rodents and which 
do not cause a behavioural activation. 
The differences between the effects of D-1 agonists in 
primates and in rodents were emphasised by the effects 
of combinations of SKF 38393 with quinpirole or apo- 
morphine. SKF 38393 inhibited the stimulation of motor 
behaviour produced by quinpirole. This contrasts with 
the ability of SKF 38393 to enhance and facilitate dis- 
tinct components of motor activity and stereotypy 
produced by the stimulation of D-2 receptors in rodents. 
It is in agreement with the ability of SKF 38393 to inhibit 
locomotor activity (Nomoto et al. 1985, 1988) and rota- 
tional behaviour (Barone et al. 1987) in a variety of 
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primate species exposed to the selective nigral neurotoxin 
1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). 
Interestingly, administration of SKF 38393 did not qual- 
itatively or quantitatively alter the motor response to 
apomorphine. The reasons for this are not clear, but may 
relate to the potent D-1 receptor agonist activity of  apo- 
morphine itself. 
On the basis of these results with SKF 38393, it ap- 
pears that in primate species D-1 receptor activation does 
not initiate motor behaviour and does not facilitate beha- 
viours induced by D-2 receptor stimulation. Rather, D-1 
receptor activation by SKF 38393 serves to depress pon- 
taneous motor  behaviour and that induced by the D-2 
agonist quinpirole in normal common marmoset. 
The administration of D-1 and D-2 agonist and an- 
tagonist drugs to common marmosets causes distinct 
behavioural effects, but these do not completely parallel 
those observed in rodents. A major difference lies in the 
effects of SKF 38393 alone and in combination with D-2 
agonists. The present results can only be interpreted in 
terms of the pharmacological ctions of SKF 38393, 
although it is feasible that the drug might exert identical 
pharmacological effects in different species but which 
resulted in the initiation of distinct behavioural re- 
sponses. It may be that in primates SKF 38393 does not 
exert a selective D-1 dopamine agonist activity. SKF 
38393 is a partial D-1 agonist and this may alter the 
response observed in primates and rodent species, since 
a high degree of endogenous D- 1 tone might result in an 
antagonist action. Alternatively, SKF 38393 might be 
metabolised to a D-1 or D-2 antagonist compound in 
vivo. However, since its behavioural effects were distinct 
from both those of SCH 23390 and ractopride in not 
inducing catalepsy, such explanations appear less likely. 
Certainly in man SKF 38393 does not produce the anti- 
parkinsonian activity that its D-1 agonist effect in 
rodents would suggest (Braun et al. 1987). The uncer- 
tainty over SKF 38393 can only be resolved when further 
selective D-1 agonists become available. However, in line 
with this concept are the results obtained with the benzer- 
goline CY 208-243, a compound which has also been 
characterised as a D-1 receptor partial agonist (Foote et 
al. 1988). Locomotor  activity of the normal common 
marmosets is stimulated by this drug (Temlett et al. 
1988a) and some patients with Parkinson's disease show- 
ed improvement (Temlett et al. 1988b). However, at this 
time it is not known whether the actions of SKF 38393 
or CY 208-243 reflect the true effect of D-1 agonist 
stimulation in a primate species. Until a centrally active 
full D-1 agonist drug is available this situation will not 
be resolved. 
An alternative xplanation may involve a different 
population of D-1 receptors and the extent o which these 
are linked to D-2 receptors. There have already been 
suggestions for different D-1 receptor populations from 
in vitro ligand binding studies in rats (Wamsley et al. 
1989). It remains unresolved whether the behavioural 
interaction between D-1 and D-2 receptors involves sites 
located on the same neurones or indeed whether these are 
even in the same brain area. 
Overall, and based on the use of SKF 38393, there 
does not appear to be a behavioural activation occurring 
via D- 1 sites or a facilitating effect of D- 1 systems on D-2 
function in the normal common marmoset. However, the 
weak inhibitory effects of both SKF 38393 and SCH 
23390 on D-2 receptor-mediated ffects might suggest 
some linkage between D-1 and D-2 systems. Although no 
absolute conclusions can be drawn at present on the role 
of D-1 systems in primates, it is clear that the effects 
observed in rodents cannot be considered predictive of 
events occurring in higher species. 
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